Purpose-built protein engineering solutions.
Simultaneous multi-property engineering.
Natural proteins function in their native context, but therapeutic and industrial applications demand properties that evolution never optimized for: elevated temperatures, non-physiological substrates or pH. And while optimizing for these conditions, retaining high target specificity is difficult.
The result of our process are proteins and enzymes that perform reliably across the full operating envelope you specify: thermostability, solubility, specificity, affinity, catalytic efficiency and ease of expression.
What we address
Revive stalled development candidates.
When a promising therapeutic candidate fails early development hurdles due to inadequate stability, poor expression, aggregation, or insufficient potency, the work isn't necessarily over. We identify the specific liabilities holding the molecule back and engineer around them.
This service is ideal for programs where early failures seem terminal but the target biology remains compelling, whether in your internal candidates or partnered assets that warrant deeper investigation. The result is not only a rescued molecule but a salvaged investment.
What we address
High-affinity binders discovery.
Discovering a novel binding protein against a challenging target, one that avoids known immunogeneity liabilities, possesses kinetic properties suitable for your application, and remains manufacturable at scale, remains one of protein engineering's key challenges. Traditional phage display, antibody libraries, and conventional scaffolds each have blind spots.
We maintain pressure on multiple properties simultaneously: binding kinetics, stability, expression, and manufacturability. The result is a binder that meets your requirements without compromises.
What we address
Reducing immunogenic liability without compromising potency.
A potent therapeutic protein that triggers strong immunogenicity in human subjects becomes clinically untenable. Whether your protein is inherently foreign (engineered scaffold), carries non-human sequence motifs, or bears post-translational modifications that trigger immune recognition, addressing immunogenic risk early dramatically improves development probability.
The goal is a molecule that retains full therapeutic potency with a substantially reduced immunogenic footprint, assessed against clinical benchmarks rather than computational predictions alone.